The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2024 | An overview of current management strategies for early-stage rectal cancer
Benjamin Adam Weinberg, MD, FACP, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, discusses the latest treatment options for patients with early-stage rectal cancer, which typically consists of chemoradiation and in some cases, the omission of surgery or radiation. In the case of MSI-high rectal cancer, immunotherapy is recommended. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Employment – Apple (I)
Stock and Other Ownership Interests – Apple (I)
Honoraria – Primum
Consulting or Advisory Role – AstraZeneca/Daiichi Sankyo; Bayer; DoMore Diagnostics; Foundation Medicine; Merus NV
Speakers’ Bureau – Bayer; Daiichi Sankyo/Astra Zeneca; Merus NV; Natera; Seagen; Sirtex Medical; Taiho Pharmaceutical
Research Funding – Abbvie (Inst); BioXCel therapeutics (Inst); Immune System Key (Inst); Ipsen (Inst); Merck (Inst)
Expert Testimony – AstraZeneca
Travel, Accommodations, Expenses – Merus NV
